|
| Code | Diagnosis | Comment | Score |
| anonymous | Malignant lymphoma (80%) High grade glial tumour (20%) | Advise immunostains for lymphoid markers (including Ki-1) and GFAP. | 100 |
| anonymous | High grade malignant tumour consistent with glioblastoma multiforme 100% | To exclude lymphoma by immunohistochemistry. | 80 |
| anonymous | Malignant lymphoma. 100% | Confirm by immunohistochemical stain for lymphoid markers. | 100 |
| anonymous | Glioblastoma multiforme (100%) | nil | 50 |
| anonymous | Diffuse large cell lymphoma | Immunostaining for LCA, L26, CD3. | 100 |
| anonymous | GLIOBLASTOMA MULTIFORME with osteosarcoma-like area. 100% | The diagnosis of GBM can be confirmed by GFAP positivity. | 50 |
| anonymous | Malignant anaplastic neoplasm. (100%) | DDx includes malignant lymphoma, especially anaplastic large cell lymphoma; metastatic anaplastic carcinoma; sarcoma including gliosarcoma; and unlikely malignant melanoma and germinoma. Favor malignant lymphoma. Confirm the diagnosis by a panel of immunostains including CD30, EMA and ALK-1 for anaplastic large cell lymphoma; LCA, B- & T-cell markers for other lymphomas; cytokeratins, in addition to other markers to exclude other differentiation, for carcinomas; GFAP and vimentin for glial sarcoma; S-100 protein and HMB-45 for melanoma; PLAP for germinoma. | 70 |
| anonymous | Brain - large cell lymphoma 100% | To apply a panel of immunomarkers to confirm lymphoid nature and to determine lineage. | 100 |
| anonymous | Malignant lymphoma, - diffuse large cell 80% - anaplastic large cell lymphoma 20% | Need to establish lineage by T and B markers. Need to rule out anaplastic large cell lymphoma by CD30(Ki-1), also need to perform ALK-1 for prognostic reason. | 100 |
| anonymous | High grade malignant neoplasm 100% DDX: Malignant lymphoma, glioblastoma multiforme | Suggest immunohistochemical staining with LCA, GFAP for delineation | 80 |
| anonymous | GLIOBLASTOMA. 100% | Suggest to perform immunostain for GFAP to confirm the diagnosis and cytokeratin and leuococyte common antigen to exlude carcinoma and lymphoma. | 80 |
| anonymous | Malignant neoplasm, favour malignant lymphoma (100%) | Glioblastoma multiforme has been considered as a ddx. - Can be distinguished by immunostaining: Lymphoma (LCA+ GFAP-), GBM (LCA- GFAP+) | 100 |
| anonymous | Giant cell glioblastoma | nil | 50 |
| anonymous | Malignant neoplasm. Favor malignant lymphoma, high grade. Probability : 100% | Would perform T & B marker, CD30, ALK, and S100, cytokeratin, GFAP to exclude malignant melanoma, metastatic carcinoma and glioblastoma multiforme. | 100 |
| anonymous | Large cell lymphoma 90% Glioblastoma multiforme 10% | Immunostains including LCA and GFAP to be performed to confirm or disprove the diagnosis of lymphoma or glioblastoma multiforme. | 100 |
| anonymous | Non-Hodgkin lymphoma (80%) Other differential diagnosis (20%) include glioblastoma multiforme and metastatic undifferentiated carcinoma. | Immunohistochemical stain for LCA, B & T-cell markers, cytokeratin and GFAP would be helpful. | 100 |